Curvebeam Ai Ltd. · ASX:CVB
Curvebeam Ai — Investor Presentation (July 2026)
20 slides from Curvebeam Ai's investor presentation, Jul 8, 2026
Slide 1: CurveBeam AI Investor Deck
For personal use only CURVEBEAM AI INVESTOR DECK (ASX:CVB) July 2026 Not for release to US wire services or distribution in the United States
Slide 2: Disclaimer
DISCLAIMER THIS PRESENTATION IS NOT FOR RELEASE TO U.S. WIRE SERVICES OR IN ANY OTHER JURISDICTION Forward looking statements WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS DOCUMENT IS NOT, AND The information given in this presentation is given for illustrative purposes only and
Slide 3: Company Highlights
• FDA cleared | TGA & CE mark | NMPA (target Q4 26) COMPANY o U.S. & German reimbursement in place1 HIGHLIGHTS For personal use only • 200+ weight bearing CT (WBCT) globally • USA co-Marketing & Distribution Agreement with Combining Weight Bearing CT (WBCT) Stryker Corp. Foot & Ankle (NYSE:SYK) imag
Slide 4: The Problem / The Solution
THE PROBLEM THE SOLUTION Traditional CT Scans don’t show the joint under its natural weight For personal use only Traditional CT Scan HiRise™ CT Scan (i.e. non-weight bearing) (i.e. weight bearing & non-weight bearing) TRADITIONAL CT HIRISE™ SCANNER SCANNER Additional Challenges: Additional Benefits
Slide 5: Product Portfolio
PRODUCT PORTFOLIO For personal use only Lead Product HiRise™ CT Scan pedCAT® InReach® (i.e. weight bearing & non-weight bearing) (i.e. weight bearing) • FDA cleared | CE Mark | TGA • FDA cleared • FDA cleared | CE Mark | TGA • Foot, ankle, hip, knee, joint • Foot and ankle • Extremity cone beam CT i
Slide 6: HiRise: A Weight Bearing Specialized CT Scanner
HIRISE™ A Weight Bearing Specialized CT Scanner For personal use only HiRise™ lets doctors image a patient’s bones and joints under normal standing load (not just lying down). This gives more accurate joint alignment & pathology information, particularly useful in orthopedics, compared with traditio
Slide 7: Workflow for Surgeons
WORKFLOW FOR SURGEONS Quicker Time to Surgery and New Revenue Stream for the Surgeon For personal use only Recommended US/European Workflow for Total Joint Replacement (TJR) – 3 PATIENT VISITS Surgeon refers Surgeon refers CT Scan sent to patient for Bone BMD sent to Surgery Plan patient for CT surg
Slide 8: Business Model
BUSINESS MODEL For personal use only U.S. Reimbursement in place 1x Sale Recurring revenue opportunity Capital Equipment Bone Mineral Density (“BMD”) Testing HiRise™ SaaS Model o USD$410k - $465k per unit1 (A$585K – A$664K) o Expand BMD testing capability into the surgeon group practice setting o Ta
Slide 9: Expansion into SaaS Business Model
Expansion into SaaS Business Model For personal use only Targeted Bone Mineral Density (BMD) SaaS Business Model – Each HiRise in knee & Hip TJR targeting 10 BMD reports per day (5-day week, 50-week year) – Surgeon reimbursement ~US$140 ($100 to $180) per BMD report (avg. private/ Complementing our
Slide 10: Purchase Orders
PURCHASE ORDERS Fiscal Year Period Ending June 30 For personal use only FY24 FY25 FY26 Total HiRise 16 6 2 24 HiRise v2 0 10 11 21 pedCAT 3 3 0 6 InReach 0 3 1 4 LineUP 3 4 2 9 Total 22 26 16 64 FY24 FY25 FY26 Total Q1 (9/30) 3 3 4 10 Q2 (12/31) 4 10 5 19 Q3 (3/31) 5 7 5 17 Q4 (6/30) 10 6 2 18 Total
Slide 11: Global Growth Strategy
G L O B A L G R O W T H S T R AT E G Y Successful placement of HiRise™ devices four continents For personal use only NORTH AMERICA Operations HQ (Penn.) EUROPE 4 FTE Sales reps 6 Distributors GREATER CHINA Marketing Team 2 FTE Sales reps Recently announced Partner Management (Stryker) 20+ HiRise™ pa
Slide 12: Stryker Partnership
S T RY K E R PA R T N E R S H I P Partnership with Stryker Foot and Ankle (F&A) For personal use only EXISTING OPPORTUNITY NEXT OPPORTUNITY ~500 Stryker Reps / 40 Regional Managers Validation with Stryker’s Robot • Selling in the U.S. & Australia/NZ • We are working with Stryker to validate the use
Slide 13: Greater China Market Opportunity
G R E AT E R C H I N A M A R K E T O P P O R T U N I T Y Chinese Partner Opens up China, SE ASIA and Large Addressable Market For personal use only Further Milestone Payments ü China NMPA approval for HiRise™ $1m investment $10m equity investment by CVB’s $1m investment & ü Wego first 10 HiRise™ ord
Slide 14: Near Term Targeted Milestones
N E A R T E R M TA R G E T E D M I L E S T O N E S A number of near-term value-driving operational and commercial milestones For personal use only 1 First $4m License Payment received from China Partner Q1 CY26 Chinese FDA (NMPA) approval for US manufactured HiRise™ 2 & further $1m Wego Equity Inves
Slide 15: Next Generation WBCT Scanner in Development: SkyRise
N E X T G E N E R AT I O N W B C T S C A N N E R I N D E V E L O P M E N T For personal use only SKYRISE™ Entire body CT Scan – covers spine & shoulder Entire CT Scan under natural body weight Small enough for surgeon practices SKYRISE™ Next Generation Capability First prototype targeting December 2
Slide 16: Competition
COMPETITION Compact but non-natural weight bearing Lacking a one size fits all approach For personal use only • Size of competitor devices not conducive to surgeon setting PlanMed Verity • Many still are limited by multi detector computed tomography (MDCT) and the high-level radiation scans Example
Slide 17: Board of Directors
BOARD OF DIRECTORS Experienced and personally invested Board For personal use only Not for Public Distribution ROBERT LILLEY GREGORY BROWN PATRICK FISHER ARUN SINGH HASHAN DE SILVA Non-Executive Chairman, Chief Executive Officer, Non-Executive Director Executive Director, COO, CTO- Non-Executive Dir
Slide 18: Capital Raising Summary
CAPITAL RAISING SUMMARY Sources and use of funds For personal use only Use of Funds A$m Sources A$m Cash Balance as at 30 June 2026 $1.6m Sales & Marketing incl. China market launch prep $2.1m Offer proceeds $5.0m R&D costs incl. product enhancements for HiRiseTM $2.3m Total Sources1 $6.6m Supply Ch
Slide 19: International Offer Restrictions
INTERNATIONAL OFFER RESTRICTIONS International Offer Restrictions pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the Securities and Futures For personal use only This document does not constitute an offer of new ordinary shares (“New Shares”) of the Company i
Slide 20: Risk Factors
RISK FACTORS The following is a summary of the material business risks of the Group (which are not listed in order of importance or likelihood). These risks may adversely impact on the Group’s financial and operating performance and prospects. Additional business risks can be found in the Group’s An